Evidence map›Paper›PMID 28925388›Full record

ArticleCell research2017

Structural step forward for NHEJ.

Go Watanabe, Michael R Lieber, Dewight Williams

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Go WatanabeUSC Norris Comprehensive Cancer Ctr., 1441 Eastlake Ave., Los Angeles, CA 90089-9176, USA.
Michael R LieberUSC Norris Comprehensive Cancer Ctr., 1441 Eastlake Ave., Los Angeles, CA 90089-9176, USA.
Dewight WilliamsLeRoy Eyring Center for Solid State Science, Physical Sciences Bldg A-213, 901 S. Palm Walk, Tempe, AZ 85287-1704, USA.
USC Norris Comprehensive Cancer Center · USPhysical Sciences (United States) · US

Funding

MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOININGR01CA100504 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIEBER, MICHAEL R · 2003 to 2021
$5.0M
Site-Specific Recombination in Human Health & DiseaseR35GM118009 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIEBER, MICHAEL R · 2016 to 2025
$4.4M
Mechanisms of Human Lymphoid Chromosomal TranslocationR01CA196671 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LIEBER, MICHAEL R · 2016 to 2021
$1.9M
NCI NIH HHS R01 CA100504NCI NIH HHS R01 CA196671NIGMS NIH HHS R35 GM118009
6 · The paper itself

Abstract

In a recent paper published in Cell Research, a cryo-EM structure reveals the interface between DNA-PKcs and the Ku70/80:DNA complex, together forming the DNA-dependent protein kinase holoenzyme in non-homologous DNA end joining. Insight from this structure suggests how an allosteric rearrangement of DNA-PKcs driven by Ku70/80:DNA binding regulates kinase activity in this largest member of a family of structurally homologous phosphoinositide 3-kinase-related protein kinases that includes mTOR, ATR, and ATM.

Indexed as

Phosphatidylinositol 3-KinasesCryoelectron MicroscopyDNADNA-Activated Protein KinaseDNA Breaks, Double-StrandedDNA End-Joining RepairHoloenzymesHumansDNADNA-Activated Protein KinaseHoloenzymesPhosphatidylinositol 3-Kinases

Identifiers

PMID28925388
PMCPMC5674156
OpenAlexW2754519420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.